Investor Relations Home
|IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.|
The Company was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, we changed our name to IRIDEX Corporation and reincorporated in Delaware. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts. We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues. It is possible that the information we post on social media channels could be deemed to be material information. We encourage investors, our customers, and others interested in our company to review the information we post on our Facebook page (www.facebook.com/IRIDEX) and Twitter feed (https://twitter.com/IRIDEX).
|10/17/14||IRIDEX to Host MicroPulse® Worldwide 3-Day Forum at the American Academy of Ophthalmology|
|Fourteen Physicians, Eight New to the IRIDEX Podium, will Share their Experiences using MicroPulse® Laser Therapy for Retina and Glaucoma
MOUNTAIN VIEW, Calif., Oct. 17, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced today its Speakers' Forum program at the annual meeting of the American Academy of Ophthalmology to be held on October 18 – 21 at McCormick Place in Chicago. The Forum consists of a comprehensive 3-day schedule of activities at the IRIDEX booth featuring 13 Micro... |
|10/14/14||IRIDEX Expands Retinal Portfolio|
|MOUNTAIN VIEW, Calif., Oct. 14, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced today that it will introduce its new family of patented Adjustable & Intuitive Extended Reach (A&I XR) laser probes at the annual meeting of the American Academy of Ophthalmology to be held October 18 - 21 at McCormick Place in Chicago. The A&I XR laser probes are used for laser photocoagulation during vitreoretinal procedures. These new devices offer unprecedented uniformity and consiste... |
|10/07/14||IRIDEX Granted U.S. Patent for Disposable MicroPulse® Delivery Device for the Non-invasive Treatment of Glaucoma|
|MOUNTAIN VIEW, Calif., Oct. 7, 2014 /PRNewswire/ -- IRIDEX Corporation (NASDAQ:IRIX) today announced that the United States Patent and Trademark Office granted the company a patent for a new proprietary disposable delivery device. The disposable delivery device, the first of its kind, enables ophthalmologists to administer IRIDEX' proprietary MicroPulse Laser Therapy in a unique and non-invasive way. The new disposable delivery device was developed to address a broad range of glaucoma patients ... |
|10/01/14||IRIDEX Reports Strong Attendance at European Workshop for its Proprietary MicroPulse® Laser Therapy for Retina and Glaucoma Applications|
|More than 150 Physicians in Attendance
MOUNTAIN VIEW, Calif., Oct. 1, 2014 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today reported a strong physician presence and reception at this year's joint congress of the European Society of Retina Specialists (EURETINA) and European Society of Cataract and Refractive Surgeons (ESCRS) meeting in London. Among its activities at the event, IRIDEX hosted a workshop on its MicroPulse Laser Therapy to a standing room only auditorium – over 150 physi... |
|Primary IR Contact|
Chief Financial Officer and Chief Operating Officer
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.